Keyphrases
Meta-analysis
99%
Cirrhosis
95%
Systematic Meta-analysis
91%
Hepatic Encephalopathy
77%
Confidence Interval
60%
Type 2 Diabetic Patients
49%
Beneficial Effects
38%
Risk Ratio
38%
Non-alcoholic Fatty Liver Disease (NAFLD)
35%
Placebo
32%
Type 2 Diabetes Mellitus (T2DM)
31%
Glucagon-like
28%
Risk of Bias
27%
Randomized Clinical Trial
25%
Randomized Trial
20%
Branched-chain Amino Acids
20%
Harmful Effects
18%
Subgroup Analysis
18%
Inflammatory Bowel Disease
17%
Acute Pancreatitis
17%
Chronic Hepatitis C
17%
Manual Search
17%
Crohn's Disease
16%
Randomized Placebo-controlled Trial
15%
Sensitivity Analysis
15%
Low Risk
15%
Medicine and Dentistry
Meta-Analysis
100%
Liver Cirrhosis
86%
Systematic Review
69%
Hepatic Encephalopathy
55%
Patient with Type 2 Diabetes
48%
Placebo
42%
Nonalcoholic Fatty Liver
41%
Maturity Onset Diabetes of the Young
38%
Systematic Review with Meta-Analysis
33%
Randomized Controlled Trial
25%
Beta Adrenergic Receptor Blocking Agent
23%
Esophageal Varices
19%
Randomized Clinical Trial
19%
Adverse Event
18%
Clinical Study
18%
Sequential Analysis
18%
Secretion (Process)
17%
Acute Pancreatitis
17%
Observational Study
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatic Encephalopathy
55%
Liver Cirrhosis
54%
Placebo
40%
Non Insulin Dependent Diabetes Mellitus
39%
Randomized Controlled Trial
24%
Beta Adrenergic Receptor Blocking Agent
23%
Adverse Event
23%
Randomized Clinical Trial
22%
